This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

OOPS!
Sorry WS was it you?. He He

25 a share in 2 years......

mitzy........ I sometimes do not no whether to reach for the valium or the champagne when I read your predictions............ long may they continue mate...... by the way I have still not taken profit (in 5 X years) and am still accumulating........ profit taking???????? for the faint hearted (and the sensible)
Keep it here guys........... Rob308(nearly an f355)but if we hit mitzy's 25 a 550 Barchetta for sure

I'm still in from 6p rob so thats a 30 bagger already but theres more to come...been a holder for 5 years through thick and thin but its worth it..!

I wish i could believe that mitzy,i have a lot of confidence in your comments on MMG but are you really that confident? I know there is a lot of news flow to come out of MMG in the near future but as we all know with pharmaceuticals the results of trials are not always successful and shares can fall heavily on bad results.If you are that confident though i might just top up my rather small holding.
DB66

good stuff.......
I have said many times on this thread do not forget all of the other products undergoing r&d in the mmg lab in camb's by various companies, ALL of which mmg have a considerable interest in.

Mitzy, if you had the b*~~s to get in at 6pence fantastic, my lowest dip was at 15 pence but the red meat is still to come.
By the way I have done a little bottom feeding lately and picked up Medysis (mdy), up 13% today and worth a look.

Rob

Thanks for that info rob.....

Just hope we keep going up and up. Dont like putting targets on share prices.

cheers GF.

No news again and the sp is marked down which is no surprise ..

.

Well the management arent helping things with their silence but Im sure if it was bad news they would have had make public the news as per the FSA rules here,

Rule 9.2 of the Listing Rules in force on 4 July 2001 states that:
A company must notify the Company Announcements Office without delay of all relevant information which is not public knowledge concerning a change:
(a) in the companys financial condition;
(b) in the performance of its business; or
(c) in the companys expectation as to its performance;
which, if made public, would be likely to lead to substantial movement in the price of its listed securities.
The continuing obligations of a listed company set out in the Listing Rules are designed to promote full disclosure to the market of all relevant information on a timely basis. The FSA regards the continuing obligation requirements of Chapter 9 of the Listing Rules as a fundamental protection for shareholders. Observance of those continuing obligations is essential to the maintenance of an orderly market in securities and of confidence in the financial system. The FSA therefore takes the most serious view of listed companies which fail to comply with these requirements.
Ends.

One could argue of course that they would also have to report any good news which would lead to a substantial move in its price but I suppose they are looking upon the genvax as already priced in before the 18th.

Seems to be speculative selling this morning which one would expect in the current market envoirement. Best to hold tight I say and were only days away from the next big news. The shares could move very much higher.

cheers GF.

Nil Desparandum... I will let you know immediately I get the news.

Cheers Mitzy.

GF.

Hold tight ....

Mitzy you're not doing my BP any good.

MS

T Trade has just gone through for 85000 shares,could be some good news coming.

Hang on....it wont be long mickey.

News just in. Check it out everyone!!

Medical Marketing Int'l Group PLC
22 March 2005


For Immediate Release 22 March 2005


MMI ANNOUNCES CANCER VACCINES UPDATE


Medical Marketing International Group plc (LSE:MMG), the Cambridge, UK-based
pharmaceutical development company announces progress on its vaccine biobaby
Genvax.

Investor update on the status of clinical studies using the DNA fusion
gene technology.

Conclusion of worldwide exclusive licence from Cancer Research
Technology Limited to commercialise the DNA fusion gene technology.

MMI investment in Genvax Ltd, increasing its shareholding to 58%.

Clinical trials

Professor Freda Stevenson, Professor of Immunology at the University of
Southampton, presented on the use of DNA fusion gene vaccines against cancer,
including preclinical developments and clinical testing, at the second Annual
DNA Vaccines Forum, London on 18th March 2005. The presented case-study included
an overview of the fusion gene concept and the clinical testing of the DNA
fusion gene vaccines against lymphoma; the first in a series of human clinical
trials using novel vaccines that use tetanus toxin to boost the immune response
against cancer.

The trials to-date have been funded by major cancer charities including The
Leukaemia Research Fund (LRF) and Cancer Research UK. This first clinical trial
was a dose escalation study involving 25 patients with follicular lymphoma, a
cancer of the lymph glands. Patients were recruited to the trial between 2001
and 2004. A majority of patients have shown an immunological response to the
vaccine. Side effects include mild-flu like symptoms, however no safety or
tolerability issues have been reported. The full results of this study will be
reported by Cancer Research UK and LRF.

In addition to the lymphoma clinical trial, two pilot clinical trials in
patients with myeloma (cancer of the bone marrow) are ongoing. At the University
of Southampton, the DNA fusion gene vaccine technology is being evaluated in a
clinical trial targeting prostate cancer. A further clinical trial, funded by
Cancer Research UK, is planned for later this year with vaccines targeted to
colon cancer and other solid tumours such as lung or stomach cancer (tumours
that express the cancer antigen CEA).

Licence

Genvax announces that it has concluded an exclusive worldwide licence with
Cancer Research Technology Limited (CRT), the specialist oncology technology
transfer and development company, for the commercialisation rights to the novel
vaccines that use immunostimulants, including tetanus toxin, to boost the immune
response. The vaccines were invented by Prof. Stevenson and her world-class
research team at the University of Southampton.

Investment

MMI will make a further investment in Genvax (from within existing budgets,
conditional on certain commercial milestones being achieved) to support the
ongoing commercial development of the cancer therapies based on this DNA vaccine
technology. As a result of this investment, MMI's stake in Genvax will increase
from 50% to 58%. This new investment will be used by Genvax to progress the
commercial development of the cancer therapies, and will include:

The development of the core technology at the University of Southampton
under the direction of Professor Freda Stevenson.

Clinical development of commercial vaccine constructs under the direction
of Dr Christian Ottensmeier.

Funding will also support the development of the manufacturing process for
the DNA vaccines at the National Blood Service GMP facility in Bristol.

The investment will also support the maintenance and continued prosecution
of the patent portfolio surrounding the use of immunostimulants in DNA
vaccines, including tetanus toxin.

Commenting on these announcements, David Best, Chairman of MMI Group and Genvax,
said 'Cancer is now the main cause of premature death in the western world. By
working with the major cancer charities, the world class research team at the
University of Southampton and the National Blood Service, together we now have
the potential to improve the lives of patients with cancer and to keep the UK at
the forefront of medicine'.


For further information, please contact:
David Best - Executive Chairman
MMI Group Tel: +44 (0)1223 477677

www.mmigroup.co.uk


Lisa Baderoon/Rebecca Skye Dietrich
Buchanan Communications Tel: +44 (0)20 7466 5000

lisab@buchanan.uk.com

duplicated rns removed

Annoucement out now.. right on Q...